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doi:10.1016/j.jtcvs.2003.11.036170 The Journal of Thoracic and CardioBackground: Restoration of blood flow to the ischemic heart may paradoxically
exacerbate tissue injury (ischemia/reperfusion injury). Toll-like receptor 4, ex-
pressed on several cell types, including cardiomyocytes, is a mediator of the host
inflammatory response to infection. Because ischemia/reperfusion injury is charac-
terized by an acute inflammatory reaction, we investigated toll-like receptor 4
activation in a murine model of regional myocardial ischemia/reperfusion injury.
We used C3H/HeJ mice, which express a nonfunctional toll-like receptor 4, to
assess the pertinence of this receptor to tissue injury after reperfusion of ischemic
myocardium.
Methods: Wild-type mice (C3H/HeN) or toll-like receptor 4 mutant mice (C3H/HeJ)
were subjected to 60 minutes of regional myocardial ischemia followed by 2 hours
of reperfusion. At the end of reperfusion, the area at risk and the myocardial infarct
size were measured as the end point of myocardial ischemia/reperfusion injury.
Myocardial mitogen-activated protein kinase activation was measured by Western
blotting, and nuclear translocation of nuclear factor-B and activator protein-1 was
determined by electrophoretic mobility shift assay. Ischemia/reperfusion–injured
myocardium was also assessed by ribonuclease protection assay for expression of
inflammatory mediators (tumor necrosis factor-, interleukin-1, monocyte chemo-
tactic factor-1, and interleukin-6).
Results: The area at risk was similar for all groups after myocardial ischemia/
reperfusion injury. There was a 40% reduction in infarct size (as a percentage of the
area at risk) in C3H/HeJ mice compared with C3H/HeN mice (P .001). Within the
myocardium, significant activation of c-Jun N-terminal kinase, p38, and extracel-
lular signal-regulated kinase was observed in both strains after ischemia and during
reperfusion as compared with an absence of mitogen-activated protein kinase
activation during sham operations; however, c-Jun N-terminal kinase activity, but
not p38 or extracellular signal-regulated kinase activity, was significantly reduced in
C3H/HeJ mice (P  .05). In both groups, nuclear factor-B and activator protein-1
nuclear translocation occurred in the myocardium during myocardial ischemia/
reperfusion injury, but, by densitometric analysis, nuclear translocation of nuclear
factor-B and activator protein-1 was significantly decreased in C3H/HeJ mice
compared with C3H/HeN mice. Interleukin-1, monocyte chemotactic factor-1, and
interleukin-6 were detectable in reperfused ischemic myocardium but were not
detected in sham-operated myocardium; the expression of each of these mediators
was significantly decreased in the myocardial tissue of C3H/HeJ mice when com-
pared with expression in the control C3H/HeN mouse strain.
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PConclusions: Our data suggest that toll-like receptor 4 may mediate, at least in part,
myocardial ischemia/reperfusion injury. Inhibition of toll-like receptor 4 activation
may be a potential therapeutic target to attenuate ischemia/reperfusion-induced
tissue damage in the clinical setting.Toll-like receptors (TLRs) have a central rolein innate immunity and inflammation.1Among the family of TLRs, TLR4 has beenthe focus of particular interest since its rec-ognition as a receptor for lipopolysaccharide(LPS; endotoxin).2-4 Of interest, TLR4
seems to bind molecular structures other than LPS, such as
paclitaxel, fibronectin, fibrin and fibrinogen, extracellular
matrix fragments, and heat-shock proteins 60 (HSP-60) and
70 (HSP-70).5-11 Thus, TLR4 may be activated in condi-
tions other than gram-negative infection.
The cytoplasmic portions of TLRs share structural and
signaling similarities with the receptor for interleukin (IL)-
1.12 With binding of ligand, TLR4 activates signaling path-
ways that lead to nuclear translocation of nuclear factor
(NF)-B, which promotes the expression of several inflam-
matory mediators, including tumor necrosis factor (TNF)-,
IL-1, IL-6, and IL-8.13-15 TLR4, initially demonstrated in
monocytes, has since been shown to be expressed in other
tissues, including the heart.16 Injured human and murine
myocardium have intense TLR4 expression.15 It is interest-
ing to note that the expression of TLR4 within the heart is
mostly in cardiomyocytes—cells that lack any identified
role in immunity.
TLR4 is linked to mitogen-activated protein kinase
(MAPK) activation. MAPKs, such as p38 and c-Jun N-
terminal kinase (JNK), are activated during myocardial
ischemia/reperfusion (I/R) injury (see review17), an event
that induces an acute inflammatory reaction. We therefore
hypothesized that TLR4, which elicits an inflammatory re-
sponse on stimulation, mediates I/R injury in the heart. To
test this hypothesis, we compared myocardial I/R injury
between 2 strains of mice: C3H/HeJ and C3H/HeN. C3H/
HeJ is a strain of mice that contains a missense mutation in
the intracellular portion of TLR4 that prevents the activation
of the remainder of the downstream signaling pathways.2,3
C3H/HeN is the mouse strain used as a wild-type control.
We demonstrated in this study that after 60 minutes of regional
myocardial ischemia, C3H/HeJ mice have a smaller area of
infarction after reperfusion than C3H/HeN mice: this suggests
participation of TLR4 in myocardial I/R injury.
Materials and Methods
Experimental Groups
C3H/HeJ mutant mice or C3H/HeN control mice were subjected tofollowed by reperfu-
The Journal of Thoracision (Figure 1). Infarction size and cytokine messenger RNA
(mRNA) levels were measured at the end of the 120-minute
reperfusion period. Three MAPKs (p38 MAPK, JNK, and extra-
cellular signal-regulated kinase [ERK]) and two transcription fac-
tors (NF-B and activator protein [AP]-1) were examined after 15
and 30 minutes of reperfusion, respectively.
Murine Model of Regional Myocardial I/R
A murine model of in situ regional myocardial I/R injury was used,
as previously described.18 All animals were maintained in accor-
dance with the Guide for the Care and Use of Laboratory Animals
published by the US National Institutes of Health (NIH; NIH
Publication no. 85-23, revised 1996) and also with the guidelines
of the Animal Care and Use Committee of the University of
Washington. Before experimentation, all animals were housed in a
room with a 22°C temperature, 41% relative humidity, and 12-/
12-hour light/dark cycles in the animal care wing and were al-
lowed access to water and food ad libitum.
General anesthesia was achieved with intraperitoneal pentobar-
bital sodium (Abbott Laboratories, North Chicago, Ill; 100 mg/kg).
In all groups, anesthesia was confirmed by lack of a foot with-
drawal reflex. A middle cervical incision was made, and a section
of PE-90 tubing was passed through the exposed trachea until the
tip was 2 mm below the larynx. Mechanical ventilation (model 687
mouse ventilator; Harvard Apparatus, Holliston, Mass) was set to
ensure normal physiologic parameters after serial blood gases were
obtained in pilot studies. Temperature was monitored via a rectal
temperature probe (YSI Series 400 temperature probe; Yellow
Springs, Ohio) and maintained at 37°C with a heating lamp. A left
parasternotomy was performed under the dissecting microscope
(Zeiss Operating Microscope, OPMI 6-SDFC; Oberkochen, Ger-
many) through careful division of 3 ribs in a cephalocaudal direc-
tion parallel to the sternum, and the pericardium was reflected to
expose the heart. A 7-0 silk suture (Tyco Health Care, US Surgical,
Norwalk, Conn) on an HE-7 needle was passed behind the left
anterior descending (LAD) artery just below the left atrial append-
age. A Rumel-type snare was created by passing both ends of the
suture through the tip of a 22-gauge angiocatheter that could then
be tightened and released by sliding a Voss clip down on the
angiocatheter for ischemia and reperfusion, respectively. Effective
occlusion of the LAD was visually confirmed by blanching of the
left ventricle (LV) and subsequent hyperemia with release of the
snare. After 60 minutes of ischemia, the occlusive snare was
released to allow reperfusion of up to 2 hours (Figure 1). Sham
mice underwent the same surgical procedures except that the
suture was not snared. At the completion of reperfusion, hearts
were rapidly explanted for molecular analyses. The LV was dis-
sected free, rinsed in 0.9% saline, snap-frozen in liquid nitrogen,
and stored at 80°C until subsequent analysis. Hearts that were
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after 2 hours of reperfusion.
Determination of AAR and Infarct Size
At the completion of the experimental protocol, the LAD was
reoccluded, and 4% Evans blue dye was injected into the aortic
root to determine AAR (unstained area). Hearts were then ex-
planted, rinsed in 0.9% normal saline, embedded in 1% agarose gel
(UltraPure agarose; Invitrogen, Carlsbad, Calif) in phosphate-buff-
ered saline (pH 7.4), and sliced into 1-mm-thick sections parallel
to the atrioventricular groove. Each heart section was incubated in
1% triphenyltetrazolium chloride at 37°C for 10 minutes and in
10% formalin for 24 hours and was then weighed and photo-
graphed with a digital camera (Coolpix 950; Nikon, Tokyo, Japan).
AAR and infarct area (unstained by triphenyltetrazolium chloride)
were measured by using computer planimetry (ImageJ 1.21; Na-
tional Institutes of Health public domain, http://rsb.info.nih.gov/
ij), and the average values were recorded. These areas were mea-
sured in a blinded fashion by an observer unaware of the
experimental groups. Infarct volumes were calculated and ex-
pressed as a percentage of AAR.
Preparation of Cytosolic and Nuclear Proteins
Frozen-tissue samples of the LV were ground into a fine powder
and homogenized in ice-cold lysis buffer. The homogenates were
centrifuged at 15,000g at 4°C for 10 minutes, and the supernatants
were collected as whole myocardial extracts.
For nuclear extractions, heart tissue samples were suspended in
an ice-cold low-salt buffer containing 0.6% Nonidet P-40 (Sigma,
St Louis, Mo). The solution was homogenized and centrifuged at
350g at 4°C for 20 seconds. The pellet was discarded, and the
supernatant was centrifuged again at 15,000g at 4°C for 10 min-
utes. The supernatant was saved as cytosolic extract; the pellet was
suspended in 40 L of high-salt buffer* at 4°C for 20 minutes.
This solution was then centrifuged at 15,000g at 4°C for 10
minutes, and the supernatant was collected as the nuclear protein
extract. Final protein concentrations of these extracts were deter-
mined by using the bicinchoninic acid method (Pierce Biotechnol-
ogy, Inc, Rockford, Ill). Samples were stored at 80°C until the
time of assay.
*Hepes 20 mmol/L, MgCl2 1.5 mmol/L, NaCl 420 mmol/L, EDTA 0.2
Figure 1. Experimental groups. Wild-type control C3H
minutes of regional myocardial ischemia and 120 mi
transcription factors (NF-B and AP-1), and infarction s
120 minutes, respectively.mmol/L, and glycerol 25%.
172 The Journal of Thoracic and Cardiovascular Surgery ● AuguWestern Immunoblotting Assay for Phosphorylation of
MAPKs
Whole-cell myocardial extracts were resolved on 10% to 15%
sodium dodecyl sulfate-polyacrylamide electrophoretic gels as
previously described.19 Gels were transferred to polyvinylidene
difluoride membranes, washed, and incubated with primary anti-
bodies for the activated, phosphorylated forms of p38, ERK, and
JNK (1:1000; Cell Signaling Technology Inc, Beverly, Mass).
Blots were also reprobed with antibody for total protein (p38,
ERK, or JNK). Blots were incubated with horseradish peroxidase–
conjugated secondary antibody (1:2000) in blocking buffer with
gentle agitation for 1 hour at room temperature. Immunoreactivity
was detected with enhanced chemiluminescence (Pierce) and
quantitated with densitometry (NIH Image 1.62). The ratio of
phosphorylated- to total MAPK immunoreactivity was determined
for each sample, and the results were expressed as fold activation
over a control.
Electrophoretic Mobility Shift Assays for NF-B and
AP-1 Activity
Electrophoretic mobility shift assays (EMSA) using an oligonu-
cleotide containing the consensus sequence motifs for NF-B
binding (5'-AGTTGAGGGGACTTTCCCAGGC-3') and AP-1
binding (5'CGCTTGATGAGTCAGCCGGAA-3'; Promega, Mad-
ison, Wis) were performed as previously described.20 Densitom-
etry was performed with NIH Image 1.62. The results were ex-
pressed as fold activation over control.
Ribonuclease Protection Assay
Total RNA was isolated from frozen tissue samples by the guani-
dinium thiocyanate-phenol-chloroform method. RNA integrity
was confirmed by agarose gel electrophoresis and quantitated by
optical density measurements at 260 nm. RNA was evaluated with
an RPA III Ribonuclease Protection Assay Kit (Ambion Inc,
Austin, Tex) and a customized mouse cytokines template (Ribo-
quant Multi-Probe Template Set; BD Biosciences Pharmingen,
San Diego, Calif). In vitro transcription was performed in buffer
supplemented with [32P]uridine triphosphate (PerkinElmer, Inc.,
Wellesley, Mass) and T7 RNA polymerase (MAXIscript T7 Kit;
Ambion). Labeling efficiency was determined by measuring Cher-
nokov activity in a scintillation counter. Each riboprobe was di-
luted to the optimal activity (defined by the manufacturer), added
mice and TLR4 mutant C3H/HeJ mice underwent 60
of reperfusion. MAPKs (p38 MAPK, JNK, and ERK),
nd cytokine mRNA levels were measured at 15, 30, and/HeN
nutes
ize ato 20 g of heart RNA, heated for 3 minutes at 95°C, and then
st 2004
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Phybridized at 56°C overnight. After ribonuclease and proteinase K
treatment, protected RNA hybrids were purified by phenol and
chloroform extraction and ammonium acetate and ethanol precip-
itation and then separated by electrophoresis on 5% polyacryl-
amide/8 mol/L urea gels. Gels were dried and subjected to auto-
radiography. Densitometric analysis was performed with NIH
Image 1.62.
Statistical Analysis
All data are expressed as mean  SEM. The significance of the
difference between group means was analyzed by analysis of
variance with post hoc comparisons by the Scheffe´ protected least
significant difference test. All statistical analyses were performed
with StatView 6.0 (SAS Institute Inc, Cary, NC).
Results
Myocardial Infarction
Wild-type (C3H/HeN) and TLR4 mutant (C3H/HeJ) mice
underwent thoracotomy and occlusion of the LAD to induce
regional I/R injury to the LV severe enough to produce an
infarct. The AAR was defined as the area of the LV that lost
perfusion during temporary occlusion of the LAD; the mean
AAR was similar in both groups (C3H/HeN AAR, 43.9%
4%; C3H/HeJ AAR, 36.1%  2%; P  .10). Following
release of the ligature after 60 minutes of ischemia, the
AAR was reperfused for 2 hours, and infarct size within the
AAR was expressed as a percentage of the AAR. C3H/HeN
mice (wild-type TLR4) had a mean infarct size of 36.2% 
2.7% (n  8). In contrast, C3H/HeJ (mutant TLR4) mice
had a distinctly smaller infarct size of 22.5%  2.4% (n 
11), a difference that was highly significant (P  .001;
Figure 2). Thus, mutation of the TLR4 gene had a protective
effect during myocardial I/R injury.
Activation of MAPKs
Activation of MAPK signaling cascades downstream of
TLR4 in LV myocardium from C3H/HeN (n  5) and
C3H/HeJ (n  5) mice was compared after 60 minutes of
ischemia and 15 minutes of reperfusion. In the C3H/HeN
mice, all 3 MAPKs were activated (Figure 3, A), compared
with undetectable levels in the LV myocardium of sham-
operated control mice (data not shown). The activation of all
3 MAPKs was also detected in the I/R-injured myocardium
of C3H/HeJ mice (Figure 3, A). However, densitometric
analysis of immunoblots for the phosphorylated, activated
form of JNK revealed significantly less activated JNK in the
myocardium of C3H/HeJ mice (mutant TLR4) compared
with levels of activated JNK in C3H/HeN (wild-type) I/R-
injured myocardium (P  .05). Total protein loading for
each kinase was controlled by immunoblotting with an
antibody that recognizes the total MAPK present in the
sample.
The Journal of ThoraciActivation of Transcription Factors (NF-B and AP-1)
Activation of NF-B and AP-1 was determined by using
EMSA to measure nuclear translocation during myocar-
dial I/R injury. EMSAs revealed activation of both
NF-B and AP-1 in both C3H/HeJ and C3H/HeN mice.
However, by densitometric analysis of the gels, with
normalization of band density to total protein loaded, the
apparent amounts of NF-B and AP-1 translocations
were significantly reduced in C3H/HeJ mice compared
with wild-type controls (C3H/HeN; P  .05; Figure 3,
B). Neither NF-B activation nor AP-1 activation was
observed at any point in any experiment during the reper-
fusion period in the sham-operated C3H/HeN mice (data
not shown).
Expression of Inflammatory Cytokines and
Chemokines
The mRNA expression of TNF, IL-1, IL-6, and monocyte
chemotactic factor (MCP)-1 in cytosolic fractions of ho-
mogenized LV from sham-operated wild-type C3H/HeN
and TLR4 mutant C3H/HeJ mice were examined after 60
minutes of ischemia and 120 minutes of reperfusion for
each strain (Figure 4). Myocardial I/R in C3H/HeN mice (n
 4) induced upregulation of IL-1, IL-6, and, most promi-
nently, MCP-1 when compared with sham controls, in
which accumulation of mRNA for IL-1, MCP-1, and IL-6
was only barely detectable. However, IL-1, MCP-1, and
IL-6 were not detected in C3H/HeJ mice during myocardial
Figure 2. Myocardial infarction size. After 60 minutes of ischemia
and 120 minutes of reperfusion, both C3H/HeN wild-type mice
(WT) and C3H/HeJ TLR4 mutant mice had similar areas at risk
within the LV (AAR/LV). However, the infarct size (Infarct/AAR)
was 40% less in mutant compared with WT mice (WT, 36.2% 
2.7% infarction; mutant, 22.5%  2.4% infarction).I/R injury (n  4). As shown in Figure 4, a small amount of
c and Cardiovascular Surgery ● Volume 128, Number 2 173
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cardial I/R injury, but not in the other 3 experiments and in
none of the 4 experiments with C3H/HeJ mice. Quantifica-
tion of mRNA levels by densitometry revealed that the
differences in expression of IL-1, MCP-1, and IL-6 between
C3H/HeN and C3H/HeJ strains were all significant (P 
Figure 3. Western immunoblotting MAPK activation
myocardium from C3H/HeJ mice after myocardial I/R in
mutant mice were subjected to 60 minutes of ischemi
and ERK compared with their respective nonischemic
observed in the degree of activation between WT I/R
resulted in strong activation of JNK in WT and TLR4 m
significantly reduced in the mutant mice (P < .05). Tw
(n  5). Phosphorylation results are shown as -fold i
samples from C3H/HeJ TLR4 mutant mice (mutant) and C
AP-1 after 30 minutes of reperfusion. Myocardial I/R re
AP-1 in both WT and mutant mice when compared w
degree of activation was significantly reduced for both
results are shown as -fold increase over the control
decrease compared with the WT level..05).
174 The Journal of Thoracic and Cardiovascular Surgery ● AuguDiscussion
We report a new, pathologic function for TLR4 and dem-
onstrate the participation of TLR4 in myocardial I/R injury.
To demonstrate the role of this receptor in injury of reper-
fused, ischemic myocardium, we used a strain of mice,
C3H/HeJ,21 with a known spontaneous mutation in tlr4, the
22
EMSA nuclear translocation of NF-B and AP-1 in
Both C3H/HeN wild-type mice (WT) and C3H/HeJ TLR4
Western immunoblots are shown for p38 MAPK, JNK,
ols at 15 minutes of reperfusion. No differences were
mutant I/R for p38 MAPK or ERK (P  NS). I/R also
t mice. However, the degree of activation of JNK was
resentative samples in each of the groups are shown
se over control level. B, Nuclear myocardial protein
eN wild-type mice (WT) were analyzed for NF-B and
d in activation of the transcription factors NF-B and
their respective nonischemic controls. However, the
B and AP-1 in the TLR4 mutant mice (P < .05). EMSA












levegene encoding TLR4. This mutation, in the cytoplasmic
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Pportion of TLR4, likely disrupts the engagement of TLR4
with adapter molecules that link TLR4 to downstream sig-
naling pathways (Figure 5). IL-1 receptor signaling, which
shares most of the same adapter molecules with TLR4, is
predictably unaffected in C3H/HeJ mice.23 Additional pro-
teins, CD14 and myeloid differentiation-2, are required for
recognition of LPS by TLR4 at the cell surface. The com-
plex of LPS, TLR4, CD14, and MD-2 is thought to induce
dimerization and activation of TLR4. Once TLR4 is acti-
Figure 4. Ribonuclease protection assay for cytokine/c
was induced in mouse hearts (as described in Materia
minutes of reperfusion. At the end of the reperfusion p
samples from sham-operated C3H/HeN mice, C3H/HeN
then analyzed for (A) TNF-, IL-1, MCP-1, IL-6, contro
nase (GAPDH). B, The expression of cytokines and chem
However, the expression of IL-1, MCP-1, and IL-6 wa
the WT mice (P < .05). *Significant increase over shamvated, the cytoplastic portion of the receptor joins with the
The Journal of Thoraciadapter protein MyD88. MyD88 then attracts the protein
kinase IL-1 receptor–associated kinase. IL-1 receptor–asso-
ciated kinase is phosphorylated and activated during contact
with MyD88 and in turn phosphorylates a third adapter,
TNF-associated factor-6. TNF-associated factor-6 is be-
lieved to activate MAPKs, which directly or indirectly ac-
tivate a set of kinases that phosphorylate IB, thus targeting
inhibitor B for degradation. Degradation of IB releases
NF-B, which translocates into the nucleus, where it pro-
kine mRNA expression. Regional myocardial I/R injury
d Methods) by 60 minutes of ischemia followed by 120
, hearts were harvested and frozen. Myocardial RNA
-type mice (WT), and C3H/HeJ TLR4 mutant mice were
NA L-32, and glyceraldehyde-3-phosphate dehydroge-
es (TNF-, IL-1, MCP-1, and IL-6) was induced in WT.
ificantly less in the TLR4 mutant mice compared with







levmotes the transcription of a wide variety of genes that
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(IL-1R) superfamily members. TLR4 (left) and IL-1R (right) are depicted in this figure showing an extracellular
domain and a cytoplasmic domain for each. TLR/IL-1Rs are thought to cluster through the course of binding ligand;
LPS interaction with TLR4 also requires CD14 and MD-2 (not shown). Presumably TLR4 and possibly other TLRs are
activated by oxidative stress during myocardial I/R injury, either by binding a putative endogenous ligand that
circulates in response to myocardial I/R injury or because of physical alteration by oxygen radical species of the
receptor-plasma membrane environment, thus causing TLR4 activation in the absence of ligand. A receptor dimer
recruits the adapter molecule MyD88. MyD88, in turn, recruits interleukin-1–associated kinase-1 (IRAK-1) and
tumor necrosis factor receptor–associated factor-6 (TRAF-6) to form a signalosome. IRAK-1, TRAF-6, and other
accessory molecules leave the cytoplasmic portion of TLR4 or IL-1R, and, at the plasma membrane, these adapters
associate with TGF--activated kinase-1 (TAK1). TAK1 is a MAP kinase kinase that leads to JNK activation and
AP-1 activity in the nucleus. TAK1 may also lead to the activation of IB kinase, which phosphorylates IB,
targeting IB for degradation. NF-B, freed of IB inhibition, translocates to the nucleus to promote the
transcription of genes encoding proteins that mediate inflammation, apoptosis, or antiapoptotic pathways. TLR4
from C3H/HeJ is illustrated with an intact extracellular domain capable of binding ligand and a cytoplasmic
domain incapable of recruitment of MyD88; in contrast, wild-type (C3H/HeN) does recruit MyD88 as the first step
in TLR4 transmembrane signaling.
176 The Journal of Thoracic and Cardiovascular Surgery ● August 2004
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inflammatory response or proteins that inhibit apoptotic cell
death.
The mechanism of TLR4 activation by oxidative stress in
the absence of LPS remains to be elucidated. TLRs are now
known to recognize certain host molecules, including fibrin
and fibrinogen, HSP-60 and HSP-70, fibronectin, and com-
ponents of the extracellular matrix.5,7-11 The apparent rec-
ognition by TLR4 of molecular structures other than LPS
may explain activation of this receptor in the setting of
myocardial I/R injury. During myocardial I/R injury, intra-
cellular HSP-60 and HSP-70 may be released from dead or
dying cells within the necrotic area of myocardium damage
during ischemia. Extracellular HSPs may then diffuse into
the surrounding ischemic zone during reperfusion and acti-
vate TLR4 on still-viable cells. The cellular events in car-
diomyocytes that result in cytotoxicity and extension of the
infarct remain to be identified. Similarly, TLR4-bearing
cells within the AAR that regulate inflammation, such as
monocytes, macrophages, and endothelial cells, may be
activated through a TLR4 signal by the oxidative stress of
myocardial I/R, leading to the initiation and advancement of
an inflammatory response. An inflammatory response trig-
gered by myocardial I/R injury, in theory, irreversibly dam-
ages potentially viable tissue surrounding an infarct, thereby
further extending it.
Although C3H/HeJ mice are more susceptible to infec-
tion with gram-negative bacteria, TLR4 blockade has been
examined as a treatment for endotoxemia.24-26 E5564 is a
structural analog of the lipid A portion of LPS and is a
potent antagonist of the biochemical and physiologic effects
of LPS in several in vitro and in vivo models. E5564 is
currently under clinical development as a possible therapeu-
tic agent for the treatment of sepsis.26 Whether E5564 can
block binding of non-LPS structures to TLR4 in myocardial
I/R injury remains to be determined.
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Dr Robert C. Robbins (Stanford, Calif). I had never heard of
TLR4 before getting this abstract from the program committee, so
I appreciate the opportunity to be educated in this area. Dr Chong
has done a very nice job in his opening remarks to discuss toll-like
receptors, which are recently discovered transmembrane receptor
proteins that play a central role both in the inflammatory process
and in the innate and inductive immunity process. As he pointed
out, most of the studies that I could find in the literature are based
on septic shock, but the objective of his study was to try to better
understand the involvement of TLR4 in I/R injury in the myocar-
dium.
He used wild-type animals and then a transgenic animal that
reduced the capability of toll-like receptor function, and he ob-
served that toll-like receptor mutant mice had significantly less
myocardial injury as manifested by reduction in myocardial infarct
size, cell signaling proteins, transcription factor, and cytokines that
are associated with I/R injury than did the control animals.
To comment technically about this study, I will just say that this
work was done by beating heart ligation of the LAD in 25-g mice.
These mice are about the size of the end of my finger and 10 times
smaller than most of the rats that we normally operate on. Tech-
nically it is a tour de force to even accomplish this model.
Second, the molecular biology is just another reflection of Dr
Verrier’s incredible laboratory and the infrastructure he has. The
information was well presented and the quality of the gels was
outstanding. I was able to find only 2 articles in the surgical
literature concerning TLR4. One is a recent article from the Uni-
versity of Toronto that demonstrated that the oxidative stress of
hemorrhagic shock contributed to regulation of TLR4 mRNA
expression, and then Magdi Yacoub’s group has demonstrated that
TLR4 expression was significantly increased in patients requiring
left ventricular assist device support compared with stable patients
with advanced heart failure who received cardiac transplantation.
However, the current study is novel and significant because it is the
first report, as Dr Chong has indicated, of the importance of
toll-like receptor in myocardial I/R injury. As the authors correctly
indicate, this new knowledge may lead to potential therapeutic
strategies for the reduction of myocardial injury associated with
reperfusion injury.
Dr Chong, I have just a few brief comments and questions. Do
you have any comment about future plans or why you did not do
any echocardiograms or dp/dt in these mice?
Dr Chong. Thank you for those kind comments, Dr Robbins.
Our in vivo model used infarction size as a measure of myocardial
injury. Our model is capable of producing reproducible results and
allowing us to really measure what the extent of the damage from
I/R injury is. The other variables such as dp/dt and also echocar-
diograms would only add to the data, and we are actually in the
process of acquiring an ultrasound machine that would actually
help us do that. Measurement of dp/dt and other hemodynamic
parameters would require us to purchase other equipment to mea-
sure that in an in vivo setting. We have thought about that and we
thought that the measurement of infarction size was sufficient.
Dr Robbins. I think your next level of this work is going to be
to actually allow the animals to survive and look at long-term
functional data. Your answer might sound like a cop-out to some
people, but at Stanford there is one 15-MHz probe and we have an
178 The Journal of Thoracic and Cardiovascular Surgery ● Auguincredible time trying to get our animals imaged. I agree with you
that it is a big expense and it is very tough to do, but I thought I
would bring it up.
Have you measured the actual toll-like receptor protein expres-
sion in your animals and is it possible to create a total knock-out
of this gene or would they just not survive?
Dr Chong. Another excellent question. First, the expression of
TLR4 has been shown in some studies. These studies concentrate
on the heart that has been damaged by ischemia chronically, and
they show that the expression of TLR4 over several days and
weeks is increased in the cardiomyocytes in points where the cells
are juxtaposed. In our model we have not done so. It would require
us to do an in situ hybridization for mRNA levels of TLR4 because
the time alloted for during ischemia and reperfusion we believe is
not enough to have de novo synthesis of TLR4 and to bring it up
to the surface.
The second answer is, yes, it is possible to have transgenic mice
with targeted deletion of TLR4. In fact, we are just about to get
those mice in addition to mice that have targeted deletion of very
proximal signaling molecules for all the toll-like receptors and not
just TLR4. Further, we are also collaborating with several phar-
macologic companies that have antagonists to TLR4 and are now
proceeding with clinical studies in sepsis. Our preliminary results
in our model show very promising results.
Dr Robbins. Why do you think you observed a reduction in
JNK kinase but not in p38 and ERK?
Dr Chong. That’s a great question. Myocardial I/R has been
shown in the literature to activate all 3 classes of MAP kinases,
p38, ERK, and JNK. As you know, activation of MAP kinase is
very complex and it is not as simple as I have shown here. The
activation of these kinases, as well as the signaling molecule
targets of these kinases, varies not only on the identity of the signal
but also on the duration, the strength, and the location. Because the
inflammatory response in myocardial I/R is so redundant, we
found that surprising to have found a reduction in JNK at all. It
seems that the protection we see from inhibiting TLR4 signaling
comes exclusively through JNK signaling, and we hope to inves-
tigate this further by looking at similar studies in transgenic mice
with targeted deletion of TLR4 as well as MYD88 and also MAP
kinase, kinase 3 and 6 deletions, which are the kinases for the
MAP-kinases. Those are the ones that exclusively control JNK.
Dr Robbins. Nowhere in the literature could I find information
about antagonists to toll-like receptors, so you speculated this
might be useful in clinical strategies. How would you plan for us
to do that? Would it be an antibody or how would we prevent
toll-like receptor in a clinical setting?
Dr Chong. Cellularly, the antagonist binds TLR4 and prevents
basically further downstream signaling. The first known adaptor
molecule to this receptor is called MYD88, and that is crucial to
the further downstream events of this receptor. Blocking it with a
specific antagonist would block the recruitment of this adaptor
molecule. We believe that this antagonist can be used in a variety
of settings, settings in which I/R events are involved, such as organ
transplantation, cardiopulmonary bypass, when you arrest the heart
during cardiac surgical procedures, during revascularization pro-
cedures, and so forth.
Dr Thomas Maxey (Charlottesville, Va). Dr Chong, you and
Dr Verrier again have set the mark for I/R research. As you know,
st 2004
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Pthe complex pathway of I/R injury involves certainly many recep-
tors and intracellular mediators. You have beautifully demon-
strated that this TLR4 down-regulates some of the intracellular
things, such as p38. Did you measure any of the end products of
TNF- and cellular adhesion molecules and things even more
downstream from NF-B to see whether those were down-regu-
lated as well?
Dr Chong. We measured mRNA levels of proinflammatory
mediators like those you are talking about—TNF-, interleukins,
adhesion molecules. As I have demonstrated in the ribonucleaseThe Journal of Thoracilevels, it was all up-regulated in the wild-type mice, and by all I
mean MCP-1, IL-6, and IL-1. In fact, there were actually others
that I did put up on the gel just for the sake of simplification, but
with TLR4 mutation all these levels were decreased. Now we are
planning to measure not just mRNA levels but also protein levels
as well as mRNA levels by in situ hybridization within the cell so
that we know which cell type these proteins come from. To do that,
we have to extend our reperfusion times long enough to have de
novo protein synthesis from the mRNA, and that will require
longer reperfusion times. There are some technical difficulties withprotection assay, which actually is a gel of looking at mRNA making the mice survive long enough for us to explant the heart.c and Cardiovascular Surgery ● Volume 128, Number 2 179
